comparemela.com

Latest Breaking News On - Harbour therapeutics - Page 1 : comparemela.com

Harbour BioMed Reports Full Year 2023 Financial Results

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, March 28, 2024 /PRNewswire/ Harbour BioMed , a global biopharmaceutical company committed to the discovery, development and.

Hong kongUnited kingdomUnited statesJingsong wangNona biosciencesShanghai nk cell technologyMain boardStock exchangeHarbour therapeuticsCullinan oncologyGreater chinaHarbour therapeuticGreater china rightsHualan geneticBoston childrenHarbour biomed

Harbour BioMed Announces Positive Profit Alert

/PRNewswire/ Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercialization.

United kingdomNona biosciencesJingsong wangBiomed the companyHarbour therapeuticsHarbour biomed

Harbour BioMed Announces 2023 Interim Results

/PRNewswire/ Harbour BioMed ("HBM", or the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and.

United kingdomJingsong wangNona biosciencesChina national intellectual property administrationHarbour biomedHarbour therapeuticsHarbour therapeuticGreater china

Harbour BioMed Reports Full Year 2022 Financial -2-

DJ Harbour BioMed Reports Full Year 2022 Financial Results EQS Newswire / 03/04/2023 / 12:10 UTC+8 Harbour BioMed Reports Full Year 2022 Financial Results CAMBRIDGE, Mass.; Suzhou, China; Rotterdam

Hong kongUnited statesUnited kingdomNona bioscienceNona biosciencesJingsong wangFinancial pressShanghai nk cell technologyBiomed reports full yearMain boardStock exchangeChief executiveHarbour therapeuticsDragonfly therapeuticsImmune cell engagersHarbour mice

Harbour BioMed Reports Full Year 2022 Financial Results

/PRNewswire/ Harbour BioMed ("HBM" or the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development and.

United kingdomUnited statesHong kongNona bioscienceNona biosciencesJingsong wangShanghai nk cell technologyMain boardStock exchangeChief executiveHarbour therapeuticsDragonfly therapeuticsImmune cell engagersAntibody plusNeuroendocrine neoplasmsCullinan oncology

vimarsana © 2020. All Rights Reserved.